Published in Oncotarget on May 10, 2015
A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection. Oncotarget (2016) 0.87
p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer. Oncotarget (2015) 0.79
Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients. Oncotarget (2016) 0.78
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. Genes Cancer (2016) 0.75
Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer. Gynecol Oncol Rep (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Cancer genome landscapes. Science (2013) 25.33
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
The DNA damage response and cancer therapy. Nature (2012) 5.25
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst (2013) 2.93
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev (2008) 2.30
Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev (2003) 2.14
Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol (2006) 2.11
Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med (2013) 1.94
Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest (2001) 1.81
Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res (2003) 1.72
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle (2012) 1.50
Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett (2010) 1.39
Searching for synthetic lethality in cancer. Curr Opin Genet Dev (2011) 1.34
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn (2010) 1.23
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res (2013) 1.22
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One (2012) 1.16
Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett (2009) 1.16
De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol (2001) 1.15
Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase. J Clin Invest (1987) 0.99
Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology (1999) 0.94
Cancer. Potential of the synthetic lethality principle. Science (2013) 0.94
Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer. Scand J Immunol (2012) 0.85
Synthetic genetic targeting of genome instability in cancer. Cancers (Basel) (2013) 0.83
Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev (2013) 0.83